This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Teladoc Boosts Weight Care Access With LillyDirect, Aids Growth
by Zacks Equity Research
TDOC expands weight care access with LillyDirect, boosting growth by offering affordable GLP-1 medications like Zepbound, enhancing patient outcomes and engagement.
Here's Why Ensign Group Can be a Smart Addition to Your Portfolio
by Zacks Equity Research
ENSG remains well-poised for growth on growing service revenues, an expanding healthcare portfolio and sufficient cash balance.
Here is Why Growth Investors Should Buy Option Care (OPCH) Now
by Zacks Equity Research
Option Care (OPCH) could produce exceptional returns because of its solid growth attributes.
3 Healthcare Stocks With Strong EPS Growth Potential to Buy in 2025
by Kaibalya Pravo Dey
GILD, OPCH and AVAH demonstrate resilience with impressive earnings surprise history.
3 Highly Ranked Medical Stocks to Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX,
by Shaun Pruitt
These highly ranked medical stocks have the value and essential services that investors may be looking for as tariff concerns and geopolitical tensions have started to rattle markets.
Teladoc Health Enhances Prism Platform for Better Virtual Care
by Zacks Equity Research
TDOC upgrades its Prism platform with AI-powered tools, improved referrals and data integration, enhancing care coordination to bolster its member base.
Earnings Estimates Rising for Option Care (OPCH): Will It Gain?
by Zacks Equity Research
Option Care (OPCH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
OPCH or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OPCH vs. CHE: Which Stock Is the Better Value Option?
Best Momentum Stocks to Buy for March 4th
by Zacks Equity Research
OPCH and LMAT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 4, 2025.
Option Care Health, Inc. (OPCH) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Option Care (OPCH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.